Drug
Aln Xdh
Aln Xdh: highest development phase Phase 1/2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-XDH NCT05256810 | Phase 1/2 | Gout |
Latest
No recent events.
Follow Aln Xdh on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.